1. Introduction {#sec1}
===============

Pregnant patients with severe psychiatric illnesses, such as affective disorder, are at increased risk of fetal growth restriction, preterm birth, maternal suicide, and infanticide \[[@B1]--[@B3]\]. Electroconvulsive therapy (ECT) is considered to be an effective and safe treatment option for patients with antenatal depression during pregnancy because psychotropic drugs can cause teratogenicity and problems in the neonate \[[@B4], [@B5]\]. Consequently, ECT is considered to be an effective therapy for pregnant patients with psychiatric symptoms \[[@B6]\].

In previous studies and reviews, a reduction in the fetal heart rate (FHR) and arrhythmias have been the most common ECT-related adverse effects in the fetus \[[@B6]--[@B8]\] and are attributed to inadequate perfusion of the uteroplacental circulation. Uterine contractions after ECT are often reported during the second and third trimester and might be related to elevated oxytocin \[[@B6]\]. To date, there have been no reports of fetal tachycardia. Here we report a case of fetal tachycardia that might have been caused by maternal hypoxia and uterine contractions in a pregnant woman diagnosed with major depressive disorder (MDD).

2. Case Presentation {#sec2}
====================

The patient was a 33-year-old gravida 0 para 0 and had been diagnosed with MDD at the age of 26 years. Although duloxetine had improved her depressive symptoms, she had a relapse of MDD at around 13 weeks\' gestation after cessation of duloxetine because of pregnancy at 5 weeks\' gestation. Her depressive symptoms then worsened despite resuming duloxetine and she finally attempted suicide. She was admitted to our hospital at 26 weeks\' gestation. She did not respond to duloxetine 40 mg/day and experienced loss of appetite and sustained suicidal ideation. She could not tolerate the adverse effects of duloxetine 60 mg/day or aripiprazole 3 mg/day as augmentation therapy (both resulted in headache). A switch to imipramine 25 mg/day caused akathisia, so duloxetine 40 mg/day was resumed because it was tolerated. ECT was then proposed as an adjunctive treatment. After obtaining informed consent from the patient and her family members, we administered a bilateral brief pulse of ECT to achieve a rapid response \[[@B9]\] and improve her suicidal ideation \[[@B10]\].

The patient underwent the first application of ECT at 30 weeks\' gestation and FHR was monitored by obstetricians and pediatricians using cardiotocography and fetal echocardiography before and after ECT. ECT was administered twice a week using a Thymatron® System IV machine (Somatics LLC, Lake Bluff, IL, USA). All ECT sessions used an electrical stimulus of 10%--25% to induce the appropriate generalized cerebral seizure with good efficacy. The first and second sessions of ECT caused fetal tachycardia ≥180 bpm for more than 30 minutes ([Table 1](#tab1){ref-type="table"}). At first, we assumed that the first stimulus dose of ECT had been so high that fetal tachycardia had occurred, so the stimulus dose was lowered in the second session. Nevertheless, fetal tachycardia occurred during the second session of ECT; we considered that the length of maternal apnea affected the fetal cardiac symptoms, so we started oxygenation just after the electric stimulus. The fetus did not have persistent elevation of FHR in the third, fourth, and fifth sessions of ECT. Meanwhile, cardiotocography recorded uterine contractions after ECT from the third session onward. On the sixth session of ECT, FHR monitoring showed tachycardia for around 120 minutes again. During monitoring, though cardiotocography did not show acceleration, baseline variability was within normal limits and decelerations were not seen. The patient had a partial remission (a change in her Hamilton Rating Scale for Depression-24 score from 36 to 26 points) with recovery of appetite and relief of suicidal ideation after the 6th session of ECT. We were concerned about the risk of preterm labor caused by administration of ECT and decided to terminate ECT because the uterine contractions had been longer at the most recent session (lasting around 120 minutes) than previously, and the risks of continuing ECT by then outweighed the benefits.

The patient was discharged at 34 weeks\' gestation and delivered a healthy baby (female, weighed 2,812 g, Apgar score of 9/10 at 1/5 minutes) at 38 weeks\' gestation. The infant has been followed up by the Department of Pediatrics at our hospital for two years and the patient has achieved a complete remission.

3. Discussion {#sec3}
=============

We have encountered a rare case of persistent fetal tachycardia (180--200 bpm for over 30 minutes), although reduction of FHR, including bradycardia, is a common side effect of maternal ECT \[[@B6]\]. Fetal tachycardia is defined as a heart rate over 160 bpm and is observed during fetal mild hypoxia, recovery from a hypoxygenic state, infection in utero, and maternal medical conditions (e.g., hyperthyroidism or maternal infection) and may be associated with medication (beta-agonists) \[[@B11]\]. The result of the blood tests showed no thyroid dysfunction or infection, and the patient did not take any drugs that might result in fetal tachycardia. In the present case, we considered the elevation of FHR might be caused by a long duration of maternal apnea after ECT that led to mild fetal hypoxia because the start of oxygenation was delayed after the convulsions following the first and second electric shocks. Therefore, restarting oxygenation just after the electric shock could avoid persistent fetal tachycardia from the third to fifth ECT session.

Uterine contractions occurred after the third ECT session in this case. Uterine contractions are common adverse effects of ECT during the third trimester \[[@B6], [@B8], [@B12]\]. Tocolytic agents are sometimes used to suppress contractions \[[@B12]--[@B14]\] but were not used in our patient because the duration of uterine contractions was short (10--20 minutes). However, on the last session of ECT, the patient experienced prolonged uterine contractions lasting for around 120 minutes. Uterine contractions are believed to reduce placental blood flow \[[@B15]\], which lead to fetal hypoxia. In our case, the baseline variability was within normal limits, indicating that the fetus had not developed acidosis. Therefore, we hypothesize that the sustained uterine contractions induced by ECT caused the fetal tachycardia with mild fetal hypoxia.

As far as we know, this is the first case report of fetal tachycardia caused by maternal ECT. Clinicians tend to be more interested in fetal bradycardia than in fetal tachycardia because the latter is usually less troublesome. Nevertheless, it is still important to be aware of tachycardia. Tachyarrhythmias, including tachycardia, are mainly caused by maternal infection or fetal hypoxia and can be lethal despite specific treatments \[[@B16], [@B17]\]; sustained fetal tachycardia might lead to fetal heart failure, hydrops, and polyhydramnios \[[@B11]\].

In conclusion, we have encountered a case of fetal tachycardia after ECT that was related to the duration of the fetal hypoxia induced by maternal hypoxia or uterine contractions. ECT can affect the cardiovascular system so it should be administered with careful monitoring of FHR not only for bradycardia but also for tachycardia during pregnancy. Restarting oxygenation immediately after delivery of the electric shock, especially, is important to avoid maternal apnea which leads to persistent fetal tachycardia.

Conflicts of Interest
=====================

The authors declare that there is no conflict of interest regarding the publication of this article.

###### 

Results of fetal heart rate monitoring and duration of maternal apnea at each ECT session.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  ECT   Stimulus (%)   Seizure duration, seconds   FHR, bpm   Duration of tachycardia, minutes   Uterine contraction    Maternal apnea, seconds
  ----- -------------- --------------------------- ---------- ---------------------------------- ---------------------- -------------------------
  1     15             93                          180--190   60                                 No                     110

  2     10             69                          190--200   30                                 No                     80

  3     15             100                         150        N/A                                Yes (20 minutes)       20

  4     25             25                          180--190   Several                            Yes (15 minutes)       20

  5     25             38                          150        N/A                                Yes (10 minutes)       20

  6     25             73                          180--190   Around 120                         Yes\                   20
                                                                                                 (around 120 minutes)   
  -----------------------------------------------------------------------------------------------------------------------------------------------

All values except for seizure duration are approximate. ECT, electroconvulsive therapy; FHR, fetal heart rate; N/A, not applicable.
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